What the FDA labels say about taking them together
Heparin and tirofiban
Heparin's FDA label (Heparin Sodium) of April 30, 2026 names tirofiban in its drug interactions section, and tirofiban's label names heparin too. The tirofiban label: “If bleeding cannot be controlled discontinue AGGRASTAT. Thrombocytopenia: Discontinue AGGRASTAT and heparin.”
Check it at the source: the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC); the tirofiban FDA label on DailyMed (effective January 1, 2025, Medicure International Inc).
What does the heparin label say about tirofiban?
Heparin Sodium label (Fresenius Kabi USA, LLC, April 30, 2026), drug interactionsDrugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Source: FDA drug label (Heparin Sodium, NDA017029), Fresenius Kabi USA, LLC, effective April 30, 2026 (SPL set 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5), via openFDA
Source: FDA drug label (Heparin Sodium In Sodium Chloride, NDA018609), Baxter Healthcare Corporation, effective January 3, 2022 (SPL set 0d929726-76c3-48fc-b4e7-fd06409f9fb3), via openFDA
Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed
What does the tirofiban label say about heparin?
Tirofiban label, warnings and precautionsIf bleeding cannot be controlled discontinue AGGRASTAT. ( 5.1 ) Thrombocytopenia: Discontinue AGGRASTAT and heparin.
Source: FDA drug label (AGGRASTAT), Medicure International Inc, effective January 1, 2025 (SPL set fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Heparin | Tirofiban | |
|---|---|---|
| Labeled for | Blood clots (DVT and PE), Atrial fibrillation | Heart attack and coronary artery disease |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.18 per mL 5,000 unit/mL vial | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once